Inc.(TSXV:TBP) (OTCQB:TBPMF) CEO Guy Chamberland tells Proactive the Ottawa-based biotechnology company has received positive feedback from the FDA on its investigational drug called ARDS-003, aiming to treat the coronavirus.
Chamberland says the group will soon initiate a Phase 1 clinical study.
What's more, Chamberland says the biotech has receives conditional approval to graduate to the TSX from the TSX-V.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE